drugset / Trial / NCT01836172

YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus

NCT01836172 ↗

Phase 2 Unknown 136 enrolled Han Wha Pharma Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the treatment of endothelial dysfunction in patients with diabetes mellitus.

Timeline

Start
2013-04
Primary completion
2016-12
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator YJP-14 Unknown 25 mg —
Comparator YJP-14 Unknown 50 mg —
Comparator YJP-14 Unknown 100 mg —

Indications

No indication recorded.